Respiratory News and Research

RSS

Doctors identify promising new treatment for hypophosphatasia

Doctors at Washington University School of Medicine in St. Louis, working with Shriners Hospital for Children and other institutions, have identified a promising new treatment for a rare and sometimes life-threatening bone disorder that can affect infants and young children.

8 Mar 2012

New FDA approved drug to treat infants with respiratory distress syndrome

Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.

7 Mar 2012

Smoking and lung cancer notice turns fifty but 20% Britons still smoke: Report

According to health experts, it has been five decades after doctors issued their first warning about the dangers of cigarettes. Still more than 20 percent of Britons still smoke - and unless they quit, half of them will die from the habit. Smoking has killed more than six million people in Britain since 1962, when the Royal College of Physicians (RCP) published a landmark report about the health risks of tobacco.

7 Mar 2012

FDA approves Discovery Labs' SURFAXIN to prevent Respiratory Distress Syndrome

Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.

6 Mar 2012

Merck announces results from AIT Phase III clinical study for ragweed allergy

Merck, known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen.

6 Mar 2012

Merck announces success of pill against ragweed allergy

Merck & Co. announced Monday that their experimental allergy tablet reduced allergic reactions to ragweed and helped patients use less medication to treat their symptoms.

5 Mar 2012

Asthma first aid charts launched

The National Asthma Council Australia has updated its popular First Aid for Asthma chart and launched a new paediatric Kids’ First Aid for Asthma chart, with advice reflecting the latest evidence and medications.

5 Mar 2012

Univita Health announces acquisition of All-Med Services of Florida

Univita Health, a leader in providing home-based care management, has announced the acquisition of All-Med Services of Florida (All-Med).

5 Mar 2012

Inovio's SynCon vaccine for HPV types 6 and 11 induces CD8+ T cells in mice

Inovio Pharmaceuticals, Inc. announced today that its SynCon therapeutic vaccine for human papillomavirus (HPV) types 6 and 11, which are associated with head & neck cancers and genital warts, among other conditions, induced strong antigen-specific CD8+ T cells in mice.

5 Mar 2012

RS donates new medical kit bags to save lives in Northamptonshire

RS Components (RS), the world's leading high service distributor of electronics and maintenance products and the trading brand of Electrocomponents plc, is helping to save lives in Northamptonshire after funding a life saving medical kit bag.

5 Mar 2012

Health Impact Project announces awardees of 15 new grants

The Health Impact Project, a collaboration of the Robert Wood Johnson Foundation and The Pew Charitable Trusts, announced the awardees of 15 new grants today. Selected following a nationwide call for proposals, the grantees will conduct health impact assessments (HIAs), a type of study that looks at potential health impacts of policies and projects in other sectors.

5 Mar 2012

Premature by 2 to 3 weeks may raise risk for health issues: Study

Premature babies have always thought to be at risk of health issues but till now the health prospects of babies born two to three weeks premature were considered similar to those who were born at full-term.

4 Mar 2012

Heavy DE exposure may increase risk of dying from lung cancer

Heavy diesel exhaust (DE) exposure in humans may increase the risk of dying from lung cancer, according to two papers released March 2nd by the Journal of the National Cancer Institute.

3 Mar 2012

Study shows decline in obesity rates among California school children

After years of increases in the rates of childhood obesity, a new UC Davis study shows that the increase slowed from 2003 to 2008 among California school children.

2 Mar 2012

CSL Behring to receive 2012 EURORDIS Award for pioneering work

CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions.

2 Mar 2012

Parasitic worms could offer new treatment hope for MS patients

Parasitic worms could offer a new treatment hope for patients suffering from the autoimmune disease multiple sclerosis, scientists believe.

1 Mar 2012

Scripps Florida study to focus on four new classes of pain-relieving compounds

Scripps Florida scientists have been awarded $3.1 million by the National Institute on Drug Abuse, part of the National Institutes of Health, to study and develop several new compounds that could prove to be effective in controlling pain without the unwanted side effects common with opiate drugs, such as morphine, Oxycontin, and Vicoden.

1 Mar 2012

Springer adds 6 new quarterly clinical review journals to medicine portfolio

Springer is adding six new quarterly clinical review journals to its existing medicine portfolio in March 2012. These new journals will expand the publisher's medical specialty coverage, focusing on dermatology, geriatrics/gerontology, nutrition, obesity, obstetrics/gynecology and respiratory care.

29 Feb 2012

Sleeping pills may raise risk of death: Study

According to a U.S. study, people who take certain prescription sleeping pills even once in a while may be up to five times more susceptible to early death. In the U.S., an estimated six per cent to 10 per cent of adults used the drugs in 2010.

29 Feb 2012

FDA clears Meridian Bioscience's TRU Legionella test

Meridian Bioscience, Inc. today announced that it has received FDA clearance from the U.S. Food and Drug Administration (FDA) for TRU Legionella, a new rapid assay for detection of legionellosis.

28 Feb 2012